ACTINOGEN MEDICAL LIMITED (ACW)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ACW

ACW - ACTINOGEN MEDICAL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.17
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.058

22 Sep
2026

0.000

OPEN

$0.06

0.000

HIGH

$0.06

3,270,482

LOW

$0.05

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

Last ex-div: 30/04 - ex-div 2.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-0.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx0.6
Net Operating Cash Flow xxxxxxxxxxxxxxx-17.6 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-77.46 %
Return on Invested Capital xxxxxxxxxxxxxxx-76.93 %
Return on Assets xxxxxxxxxxxxxxx-56.92 %
Return on Equity xxxxxxxxxxxxxxx-77.46 %
Return on Total Capital xxxxxxxxxxxxxxx-117.73 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-17.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx5 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx5 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx17 M
Price To Book Value xxxxxxxxxxxxxxx4.79

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx28 M
Research & Development xxxxxxxxxxxxxxx19 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

07/09/2026

1

Speculative Buy

$0.08

37.93%

Canaccord Genuity maintains a Speculative Buy rating for Actinogen Medical with a $0.08 target price ahead of topline results from the phase 2b/3 XanaMIA trial expected in November.

The study randomised 247 participants with mild to moderate Alzheimer's disease for 36 weeks of treatment to assess the efficacy of Xanamem.

The analyst views recent research as providing strong mechanistic validation for the cortisol hypothesis, noting the APOE4 genetic risk factor amplifies local neuronal cortisol signalling through Xanamem's exact target.

With 69% of genotyped trial participants carrying at least one APOE4 allele, Canaccord Genuity considers the enrolled cohort biologically appropriate and well-positioned for the upcoming readout.

A successful outcome will allow the company to progress Xanamem into a final phase 3 registration study under trial designs already agreed upon with the FDA and EMA.
Access Extra Coverage Research History >

ACW STOCK CHART

FNArena News on ACW

1
Australian Broker Call *Extra* Edition – Sep 07, 2026

Sep 07 2026 - Daily Market Reports
2
Rudi’s View: Resilient, But August Fails To Excite

Sep 02 2026 - Rudi's View
3
Australian Broker Call *Extra* Edition – Jul 22, 2026

Jul 22 2026 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Apr 23, 2026

Apr 23 2026 - Daily Market Reports
5
In Brief: Acrow, Eagers Automotive & Catapult

Apr 10 2026 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
2
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
3
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
4
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
5
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
6
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
7
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
8
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
9
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
10
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps